Sugi Predict

Sugi Predict / Compounds / SCHEMBL1015283

SCHEMBL1015283

SCHEMBL1015283

CC(C)(C)OC(=O)N1CCC(c2ccc(Br)cc2)C1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 1/20 0.58
▸ RORC P51449 2/20 0.52
▸ NAMPT P43490 1/20 0.52
▸ FPR2 P25090 6/20 0.51
▸ MAPT P10636 3/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ USP30 Q70CQ3 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ THRB P10828 1/20 0.48
▸ FPR3 P25089 2/20 0.48
▸ TP53 P04637 2/20 0.47
▸ GPR119 Q8TDV5 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1015281 1.00 PDE4B (0.58) PDE4BRORCNAMPTFPR2MAPT
SCHEMBL1673620 0.93 FPR2 (0.55) PDE4BRORCNAMPTFPR2MAPT
SCHEMBL18557979 0.93 FPR2 (0.55) PDE4BRORCNAMPTFPR2MAPT
SCHEMBL28943526 0.93 FPR2 (0.55) PDE4BRORCNAMPTFPR2MAPT
SCHEMBL180505 0.92 NAMPT (0.60) PDE4BRORCNAMPTFPR2MAPT
SCHEMBL15322683 0.92 PDE4B (0.52) PDE4BRORCNAMPTFPR2MAPT
SCHEMBL15187965 0.89 RORC (0.56) PDE4BRORCNAMPTFPR2USP30
SCHEMBL31222940 0.88 FPR2 (0.49) PDE4BRORCNAMPTFPR2MAPT
SCHEMBL12321142 0.88 PDE4B (0.60) PDE4BNAMPTMAPTALDH1A1HTT
SCHEMBL18937651 0.88 PDE4B (0.60) PDE4BNAMPTMAPTKDM4ETHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116869-A1 AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS NOVARTIS AG (CH) 2026-04-30 — — US disclosed
US-12466808-B2 Aminopyridine derivatives and their use as selective ALK-2 inhibitors NOVARTIS AG (CH) 2025-11-11 — — US disclosed
US-20250084012-A1 METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUP CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-03-13 — — US disclosed
EP-4461715-A1 METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUPS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-11-13 — — EP disclosed
EP-4442317-A2 AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS Novartis AG (CH) 2024-10-09 — — EP disclosed
CN-114014844-B Aminopyridine derivatives and their use as selective ALK-2 inhibitors 诺华股份有限公司 2024-10-01 — — CN disclosed
CN-118510741-A Method for removing t-butoxycarbonyl group 中外制药株式会社 2024-08-16 — — CN disclosed
EP-3971177-B1 AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS NOVARTIS AG (CH) 2024-06-26 — — EP disclosed
CN-116507607-A Compounds and compositions as modulators of TLR signaling 神经孔疗法股份有限公司 2023-07-28 — — CN disclosed
WO-2023132353-A1 METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUPS 中外製薬株式会社 2023-07-13 — — WO disclosed
WO-2013153479-A2 INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK PFIZER INC. (US) 2013-10-17 — — WO disclosed
US-20130267493-A1 INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK PFIZER INC. (US) 2013-10-10 — — US disclosed
US-20120245172-A1 HETEROCYCLIC AMINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2012-09-27 — — US disclosed
US-20120245172-A1 HETEROCYCLIC AMINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2012-09-27 — — US disclosed
WO-2012126922-A1 HETEROCYCLIC AMINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-09-27 — — WO disclosed
EP-2081890-B1 ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS HOFFMANN LA ROCHE (CH) 2011-01-12 — — EP disclosed
US-7776910-B2 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors ROCHE PALO ALTO LLC (US) 2010-08-17 — — US disclosed
EP-2081890-A1 ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS F. Hoffmann-Roche AG (CH) 2009-07-29 — — EP disclosed
US-20080167361-A1 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors ROCHE PALO ALTO LLC 2008-07-10 — — US disclosed
WO-2008055847-A1 ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-05-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466808-B2 Aminopyridine derivatives and their use as selective ALK-2 inhibitors ALK, ACVR1, ACVR1B PDE4B 781/4885RORC 3105/4885NAMPT 2337/4885
US-20120245172-A1 HETEROCYCLIC AMINE DERIVATIVES TAAR1, TAAR5, MTNR1A PDE4B 672/4885RORC 524/4885NAMPT 1642/4885
US-20250084012-A1 METHOD FOR REMOVING TERT-BUTOXYCARBONYL GROUP TERT, MGMT, MITF PDE4B 4757/4885RORC 1790/4885NAMPT 2165/4885
US-20080167361-A1 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors HTR6, HTR1B, HTR1F PDE4B 1026/4885RORC 3690/4885NAMPT 1558/4885
US-20260116869-A1 AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS ALK, ACVR1, ACVR1B PDE4B 2703/4885RORC 1434/4885NAMPT 4475/4885
US-20130267493-A1 INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK PRKAG1, PRKAG3, PRKAG2 PDE4B 208/4885RORC 186/4885NAMPT 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.